|
|
|
US drug shortages soar, Congressman probes "grey" marketeers
|
As the number of medicines in short supply in the US hits around 200 in 2011 so far - compared with the record 178 reported for the whole of 2010 - a leading Congressman has begun an investigation of "grey market" middleman companies, which charge exorbitant prices for prescription drugs in critically short supply.
Democratic Representative Elijah Cummings, a member of the House Committee on Oversight and Government Reform, has begun an investigation into the extent to which five such grey market companies are "making substantial profits by engaging in a form of drug speculation."
View Full Article
|
|
|
|
Sanofi wins U.S. cancer drug patent ruling |
|
(Reuters) - French drugmaker Sanofi has scored an important victory in a patent dispute with Sun Pharmaceuticals that will keep generic copies of its Eloxatin colon cancer drug off the United States market until August 2012.
View Full Article |
|
|
| Study: Orphan drugs win favored status in FDA reviews
|
| Over the last few years there's been a big increase in Big Pharma's interest in rare diseases. With Genzyme's success with drugs like Myozyme helping light the way, giants like GlaxoSmithKline, Pfizer, Merck and Novartis have been organizing their own rare disease drug shops. And the FDA's more flexible attitude in how it judges the data from clinical trials for these drugs--as well as the 7 years of marketing exclusivity they earn along with some hefty tax credits--hasn't hurt.
View Full Article
|
|
|
| IDF Online Continuing Education Course for Nurses: Primary Immunodeficiency Diseases and Immunoglobulin Therapy (5 hours)
|
The Immune Deficiency Foundation (IDF) is proud to offer this Online Continuing Education Course, developed as an initiative of the IDF Nurse Advisory Committee. This free, accredited course enhances the knowledge of the nurse clinician by providing an update on primary immunodeficiency diseases, immunoglobulin therapies and the nurse's role with these therapies.
Any nurse who is involved with administration and management of immunoglobulin therapy or the disease states where immunoglobulin is used would find this program very informative and applicable to practice.
Read
More |
|
|
|
Price-Gougers Hike Cost of Vital Drugs During Shortage |
|
'Gray market' suppliers offer medication at an average 650 percent
mark-up, survey shows |
Amid growing shortages of life-saving drugs, some back-door suppliers are capitalizing on the problem, jacking up prices for medications for cancer, high blood pressure and other serious problems by as much as 4,500 percent, a new hospital survey shows.
So-called “gray market” medical suppliers — vendors who operate
through unofficial channels — inflated prices by an average of 650
percent on drugs that were either back-ordered or completely
unavailable. |
|
View Full Article |
|
|
|
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
|
|
Doctors, Patients Gain Flexibility to Choose Preferred Route of Administration |
|
DEERFIELD, Ill., Jul 25, 2011 (BUSINESS WIRE) -- Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency (PI). |
|
View Full Article |
|
|
|
JP Morgan Comments on Trial Completion of Baxter's Alzheimer's Drug |
| “We confirmed on Wednesday that the first of Baxter's (NYSE : BAX) two phase III IVIG for Alzheimer's trials has now completed enrollment,” JP Morgan wrote in a report this morning.
|
|
View Full Article |
|
|
|
Critical U. S Drug Shortage Worsening |
|
The nation is facing an unprecedented drug shortage. From cancer
treatments to surgical sedatives to standard emergency-room
remedies, the pharmaceutical supply cabinet is increasingly bare of
the drugs of choice, according to doctors, advocacy groups, and the
FDA
View Full Article |
|
|
|
|
|
Risk of thrombotic and thromboembolic events following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
Read More
|